CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 3, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced that
“Novel protocol combining metronomic Nant-paclitaxel with HER2-targeted natural killer cells (innate immunotherapy) for HER2-positive metastatic breast cancer” CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 9, 2015-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage
CULVER CITY, Calif. --(BUSINESS WIRE)--Oct. 3, 2016-- NantKwest, Inc (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 2, 2015-- NantKwest Inc. (Nasdaq:NK) today announced that the company will be presenting at the following upcoming investment conferences in November and December: Citi 2015 Global Healthcare Conference, Jefferies 2015 Global Healthcare Conference and the
CULVER CITY, Calif. --(BUSINESS WIRE)--Sep. 10, 2016-- NantKwest, Inc (NASDAQ:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
CULVER CITY, Calif.--( BUSINESS WIRE )--NantKwest, Inc. (formerly Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, announced today the
Combination in 30 Patients with Advanced Metastatic Cancer Refractory to Multiple Previous Therapies Zero Incidence of Cytokine Release Syndrome in Any of the 300 Doses in 30 Patients All Patients Received NK Cell Infusion and Novel Cancer Memory Vaccine Combination as Outpatients with No
LOS ANGELES --(BUSINESS WIRE)--Aug. 26, 2015-- NantKwest (Nasdaq:NK), working with Ganesh Palapattu, MD and his team at the University of Michigan , along with Karen Knudsen , PhD and her group at Thomas Jefferson University , announced a $1 Million Challenge award from the Prostate Cancer
CULVER CITY, Calif. --(BUSINESS WIRE)--Jul. 25, 2017-- NantKwest Inc. (Nasdaq:NK), a clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases, and inflammatory diseases, today announced a
Successful Administration Of Off The Shelf Hank Cells In Patients With Solid Tumors Paves The Way To Nation's First Combination Innate And Adaptive NANT Cancer Vaccine Trials In Multiple Tumor Types CULVER CITY, Calif. --(BUSINESS WIRE)--Oct. 2, 2017-- NantKwest Inc.
